Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Apr 23, 2019
Table of Contents
Merck’s Keytruda has recently got the U.S. FDA approval to be administered for Kidney Cancer. The drug Keytruda was approved in combination with Pfizer’s Inlyta for the treatment of advanced renal carcinoma. This therapy could prove to be serious for competition Bristol-Myers Squibb’s immunotherapy combination of Opdivo and Yervoy.
The U.S. FDA has recently approved Naloxone also known as Narcan- the first generic nasal spray to treat Opioid overdose. Narcan, developed by Israel’s Teva Pharmaceuticals, is a pre-filled, needle-free device which is sprayed into the nostrils of the patients. Costing about USD 130 to USD 150 for a pack of two, it can help to decline a rising death toll due to Opioid overdose.
Article in PDF
NeuroSigma’s, a prescription-only medical device, Monarch external Trigeminal Nerve Stimulation (eTNS) helps in treating Attention Deficit Hyperactivity Disorder (ADHD) by offering a mild nerve stimulation. The new device has recently been permitted by the FDA to treat children of age 7-12 years suffering from ADHD. Pediatric medical devices are often not given any such priority due to the less lucrative market, but ADHD prevalence has given it momentum.
Creso Pharma, an Australian based pharmaceutical company, has won the approval from Brazilian health regulatory agency ANVISA to import and sell its first medical cannabis product cannaQIX®50, a medicated tablet designed to relieve pain. In partnership with SIN Solution, Creso will target mainly doctors working in the field of Oncology and patients suffering.
Article in PDF
